Adjust Font Sizing:

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

December 6th, 2019

Axsome Therapeutics, Inc. announced that AXS-12 (reboxetine) met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT Phase 2 trial. AXS-12 also significantly reduced excessive daytime sleepiness (EDS), and improved cognitive function, sleep quality, and sleep-related symptoms. AXS-12 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. CONCERT was a Phase 2, randomized, double-blind, placebo-controlled, crossover, multicenter, U.S. trial in which 21 patients with a diagnosis of narcolepsy with cataplexy were all treated with orally administered AXS-12 for 2 weeks, and with placebo for 2 weeks, with the treatment periods separated by 1 week of down-titration and washout.

Plans will now proceed into Phase 3 with AXS-12 which may one day offer patients a therapeutic alternative that can be efficacious across multiple symptoms while also having an acceptable safety and tolerability profile.

To read the entire announcement by Axsome, see the link from Axsome Therapeutics.

# # #
Date Created: December 6th, 2019
Last Updated: December 21st, 2023